Spots Global Cancer Trial Database for peripheral t cell lymphoma
Every month we try and update this database with for peripheral t cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) | NCT03502629 | Peripheral T Ce... | GB226 | 18 Years - | Genor Biopharma Co., Ltd. | |
| Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" | NCT04213209 | Peripheral T Ce... Pediatric Hodgk... | Brentuximab Ved... | - | Takeda | |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | NCT03719105 | NK-Cell Lymphom... NK-Cell Leukemi... Peripheral T Ce... | Methotrexate pralatraxate, Ifosfamide Dexamethasone Etoposide calaspargase pe... cyclophosphamid... Doxorubicin Prednisone Brentuximab Ved... | 1 Year - 31 Years | New York Medical College | |
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma | NCT04045470 | Cutaneous T Cel... Peripheral T Ce... | Microdevices Standard of car... Standard of car... | 18 Years - | Dana-Farber Cancer Institute | |
| Minimal Residual Disease in Peripheral T-cell Lymphoma | NCT03297697 | Peripheral T Ce... | Tumor biopsy Peripheral bloo... Lymphotrack TCR... | 18 Years - | Washington University School of Medicine | |
| Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients | NCT03079947 | Diffuse Large B... Peripheral T Ce... | 18 Years - 80 Years | Peking Union Medical College Hospital | ||
| BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | NCT04018248 | Diffuse Large B... Follicular Lymp... Chronic Lymphoc... Small Lymphocyt... B Cell Lymphoma Marginal Zone L... Waldenstrom Mac... Peripheral T Ce... | BR101801 (Phase... BR101801 (Phase... | 18 Years - | Boryung Pharmaceutical Co., Ltd | |
| Go-CHOP as the Frontline Therapy for PTCL | NCT05963347 | Peripheral T Ce... | Golidocitinib CHOP Regimen | 18 Years - | Henan Cancer Hospital | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) | NCT03268889 | Peripheral T Ce... | Chidamide | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma | NCT02753543 | Peripheral T Ce... | Chidamide | 16 Years - 75 Years | Ruijin Hospital | |
| Study to Evaluate CCS1477 in Haematological Malignancies | NCT04068597 | Haematological ... Acute Myeloid L... Non Hodgkin Lym... Multiple Myelom... Higher-risk Mye... Peripheral T Ce... | CCS1477 Pomalidomide Dexamethasone Azacitidine Venetoclax | 18 Years - | CellCentric Ltd. | |
| A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma | NCT05495100 | Peripheral T Ce... | Mitoxantrone li... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | NCT04028440 | Non-Hodgkin's L... Relapsed or Ref... Chronic Lymphob... Peripheral T Ce... | Autologous γδT ... | 18 Years - 75 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | NCT05749549 | Advanced Cancer Follicular Lymp... Peripheral T Ce... Diffuse Large B... | BR1733 | 18 Years - | Shanghai Blueray Biopharma Co., Ltd. | |
| Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma | NCT02753543 | Peripheral T Ce... | Chidamide | 16 Years - 75 Years | Ruijin Hospital | |
| Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas | NCT03071822 | Peripheral T Ce... | cisplatin ifosfamide gemcitabine L-asparaginase etoposide dexamethasone | 18 Years - 80 Years | The University of Hong Kong | |
| Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | NCT05321147 | Peripheral T Ce... | lacutamab | 18 Years - | Innate Pharma | |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | NCT04028440 | Non-Hodgkin's L... Relapsed or Ref... Chronic Lymphob... Peripheral T Ce... | Autologous γδT ... | 18 Years - 75 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma | NCT05900089 | Peripheral T Ce... | SHR0302 | 18 Years - | Henan Cancer Hospital | |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | NCT03023358 | Peripheral T Ce... | chidamide cyclophosphamid... liposomal doxor... vincristine prednisone | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides | NCT04101331 | Peripheral T Ce... Transformed Myc... | AFM13 | 18 Years - | Affimed GmbH | |
| Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | NCT06151106 | Peripheral T Ce... Relapsed Periph... Refractory T-Ce... | Chidamide combi... | 18 Years - 75 Years | The First Affiliated Hospital of Xiamen University | |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | NCT06072131 | Peripheral T Ce... | Belinostat Inje... Pralatrexate In... CHOP COP | 18 Years - | Acrotech Biopharma Inc. | |
| Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma | NCT02944812 | Peripheral T Ce... | Chidamide | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | NCT03150602 | Peripheral T Ce... Progression, Di... | Pralatrexate | 20 Years - | Taiwan Mundipharma Pharmaceuticals Ltd. | |
| Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | NCT06083701 | Peripheral T Ce... | Linperlisib in ... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma | NCT02856997 | Peripheral T Ce... | Chidamide with ... | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | NCT05749549 | Advanced Cancer Follicular Lymp... Peripheral T Ce... Diffuse Large B... | BR1733 | 18 Years - | Shanghai Blueray Biopharma Co., Ltd. | |
| The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). | NCT04457830 | Peripheral T Ce... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | NCT05559008 | Peripheral T Ce... | Azacitidine Inj... Dasatinib Linperlisib Tucidinostat SHR2554 Camrelizumab Apatinib | 18 Years - | Ruijin Hospital | |
| Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma | NCT00974324 | T Cell Lymphoma | endostar and CH... | 18 Years - 75 Years | Fudan University | |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | NCT00007345 | Cutaneous T Cel... Peripheral T Ce... | Romidepsin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | NCT03927105 | Peripheral T Ce... | Nivolumab cabiralizumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | NCT06083701 | Peripheral T Ce... | Linperlisib in ... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma | NCT04061772 | Peripheral T Ce... | Bortezomib Etoposide Cyclophosphamid... Pharmorubicin Prednisone | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | NCT05979792 | Peripheral T Ce... | CAR-T Therapy | 18 Years - 79 Years | Ruijin Hospital | |
| Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | NCT05883449 | Relapsed or Ref... Peripheral T Ce... | AFM13 AB-101 Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - | Affimed GmbH | |
| Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients | NCT03141203 | Peripheral T Ce... | Romidepsin Carfilzomib | 16 Years - | University of Birmingham | |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) | NCT05137847 | Lymphoma, T-cel... Lymphoma, T-cel... | Remitoro | - | Eisai Inc. | |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | NCT06433362 | Peripheral T Ce... | CMOEP | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Allo-hNHL (FluBuCy) | NCT00785330 | Non-Hodgkin's L... | standard GVHD p... rituximab | 18 Years - 65 Years | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | NCT05559008 | Peripheral T Ce... | Azacitidine Inj... Dasatinib Linperlisib Tucidinostat SHR2554 Camrelizumab Apatinib | 18 Years - | Ruijin Hospital | |
| Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | NCT05883449 | Relapsed or Ref... Peripheral T Ce... | AFM13 AB-101 Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - | Affimed GmbH | |
| The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma | NCT04489264 | Peripheral T Ce... | Transplant, Aut... | 18 Years - 65 Years | Peking University | |
| CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | NCT01806337 | Peripheral T-Ce... | Alemtuzumab | 18 Years - 70 Years | University of Göttingen | |
| Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas | NCT03071822 | Peripheral T Ce... | cisplatin ifosfamide gemcitabine L-asparaginase etoposide dexamethasone | 18 Years - 80 Years | The University of Hong Kong | |
| γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | NCT04028440 | Non-Hodgkin's L... Relapsed or Ref... Chronic Lymphob... Peripheral T Ce... | Autologous γδT ... | 18 Years - 75 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | NCT03023358 | Peripheral T Ce... | chidamide cyclophosphamid... liposomal doxor... vincristine prednisone | 18 Years - | Nanfang Hospital, Southern Medical University | |
| Transplantation After Complete Response In Patients With T-cell Lymphoma | NCT05444712 | Peripheral T Ce... | Chemotherapy + ... Chemotherapy + ... | 18 Years - 70 Years | Hospices Civils de Lyon | |
| A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas | NCT01280526 | Peripheral T Ce... | Romidepsin and ... Romidepsin and ... Romidepsin and ... Romidepsin and ... | 18 Years - 80 Years | The Lymphoma Academic Research Organisation | |
| Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL | NCT04548700 | Treatment-naïve Peripheral T Ce... | Dose-finding st... Dose-expansion ... | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | NCT06083701 | Peripheral T Ce... | Linperlisib in ... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | NCT03586999 | Peripheral T Ce... | Nivolumab Etoposide Prednisolone Oncovin Cyclophosphamid... Hydroxydaunorub... | 18 Years - 80 Years | University of Colorado, Denver | |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | NCT06433362 | Peripheral T Ce... | CMOEP | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma | NCT05900089 | Peripheral T Ce... | SHR0302 | 18 Years - | Henan Cancer Hospital | |
| Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) | NCT03268889 | Peripheral T Ce... | Chidamide | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). | NCT04457830 | Peripheral T Ce... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | NCT05239910 | Peripheral T Ce... | Tenalisib | 18 Years - | Rhizen Pharmaceuticals SA | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | NCT03629873 | Lymphoma, Large... Mantle Cell Lym... Peripheral T Ce... Double-hit Lymp... | Chidamide | 18 Years - 60 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) | NCT03502629 | Peripheral T Ce... | GB226 | 18 Years - | Genor Biopharma Co., Ltd. | |
| A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma | NCT04470141 | Peripheral T Ce... | SHC014748M trea... | 18 Years - | Nanjing Sanhome Pharmaceutical, Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
